http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018042096-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81fb736bb33a8f5086e3d7a3c6dc65be |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate | 2017-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e3e68f4eacfce57ebab293e0f792d16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce695bf167f322a0d7d8ef35c1cf0a74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2add09af2113c5b32c7278ce96e777f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2933b93d0974f5e36e392e6b2246faad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9bacf6f4bafc9dc8f09e402c58158fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_887579eb5677e1b79a28660d829b3f11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8704bdf1771316a49b52490136537c75 |
| publicationDate | 2018-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018042096-A1 |
| titleOfInvention | 2-quinolin-2-one derivatives as modulators of nmda receptors, compositions comprising same and use of these compounds in the treatment of diseases involving the central nervous system |
| abstract | The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indol-1-yl-(1 H )quinolin-2-one and indol-3-yl-(1 H )quinolin-2-one type, especially as medicament, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may especially be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder. |
| priorityDate | 2016-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.